TransMedics Group, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-77.5% vs price
Base Case (Median)
-50.6% vs price
Bull Case (75th pct.)
-25.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.97 | -94.4% | High (40%) |
| PE Comparable | $85.90 | -2.8% | Medium (25%) |
| Growth Trajectory DCF | $250.21 | 183.2% | Medium (20%) |
| Graham Number | $34.77 | -60.6% | Medium (40%) |
| EV/EBITDA | $43.68 | -50.6% | Medium (20%) |
| EV/FCF | $46.50 | -47.4% | Medium (20%) |
| Earnings Power Value | $4.80 | -94.6% | Medium (50%) |
Based on 7 out of 8 methods, TMDX appears overvalued at the current price of $88.35. The base case fair value of $43.68 implies 50.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.